SI1133312T1 - Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina - Google Patents
Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulinaInfo
- Publication number
- SI1133312T1 SI1133312T1 SI200030975T SI200030975T SI1133312T1 SI 1133312 T1 SI1133312 T1 SI 1133312T1 SI 200030975 T SI200030975 T SI 200030975T SI 200030975 T SI200030975 T SI 200030975T SI 1133312 T1 SI1133312 T1 SI 1133312T1
- Authority
- SI
- Slovenia
- Prior art keywords
- glucagon
- agonists
- peptide
- dependent diabetes
- insulin dependent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13979499P | 1999-06-21 | 1999-06-21 | |
PCT/US2000/015548 WO2000078333A2 (en) | 1999-06-21 | 2000-06-06 | Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes |
EP00938173A EP1133312B8 (en) | 1999-06-21 | 2000-06-06 | Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1133312T1 true SI1133312T1 (sl) | 2008-02-29 |
Family
ID=22488329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200030975T SI1133312T1 (sl) | 1999-06-21 | 2000-06-06 | Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina |
Country Status (12)
Country | Link |
---|---|
US (3) | USRE40876E1 (sl) |
EP (2) | EP1849475A1 (sl) |
AT (1) | ATE372782T1 (sl) |
AU (1) | AU5325200A (sl) |
CA (1) | CA2349865C (sl) |
CY (1) | CY1106971T1 (sl) |
DE (1) | DE60036367T2 (sl) |
DK (1) | DK1133312T3 (sl) |
ES (1) | ES2291210T3 (sl) |
PT (1) | PT1133312E (sl) |
SI (1) | SI1133312T1 (sl) |
WO (1) | WO2000078333A2 (sl) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235627B2 (en) | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US20090175821A1 (en) * | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
DK2280021T3 (en) | 1999-06-29 | 2016-05-02 | Mannkind Corp | Pharmaceutical formulations comprising insulin complexed to a diketopiperazine |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
DE60136958D1 (de) | 2000-12-01 | 2009-01-22 | Takeda Pharmaceutical | Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz |
JP2004518756A (ja) | 2001-03-07 | 2004-06-24 | ノボ ノルディスク アクティーゼルスカブ | Glp−1類似体およびpparリガンドの誘導体の組み合わせ使用 |
IL160983A0 (en) | 2001-09-24 | 2004-08-31 | Imp College Innovations Ltd | Use of pyy for preparation of a medicament for modification of feeding behavior |
FR2832064A1 (fr) * | 2001-11-13 | 2003-05-16 | Lipha | Composition pharmaceutique comprenant une glitazone et un derive de thiazolidinedione et son utilisation pour traiter le diabete |
ES2500918T3 (es) | 2001-12-21 | 2014-10-01 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina e interferón beta |
JP2005514399A (ja) * | 2001-12-21 | 2005-05-19 | スミスクライン ビーチャム コーポレーション | PPARγアクチベーターの投薬法 |
WO2003057235A2 (en) | 2002-01-10 | 2003-07-17 | Imperial College Innovations Ltd | Modification of feeding behavior |
ES2300568T3 (es) | 2002-03-20 | 2008-06-16 | Mannkind Corporation | Aparato de inhalacion. |
US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
WO2004050115A2 (en) * | 2002-12-03 | 2004-06-17 | Novo Nordisk A/S | Combination treatment using exendin-4 and thiazolidinediones |
EP1688148A1 (en) * | 2002-12-03 | 2006-08-09 | Novo Nordisk A/S | Combination treatment using exendin-4 and thiazolidinediones |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
US7638638B2 (en) | 2003-05-14 | 2009-12-29 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1577673B1 (en) * | 2004-03-15 | 2008-07-30 | F. Hoffmann-La Roche Ag | The use of BNP-type peptides and ANP-type peptides for assessing the risk of suffering from a cardiovascular complication as a consequence of volume overload |
EP2230257A1 (en) | 2004-04-23 | 2010-09-22 | ConjuChem Biotechnologies Inc. | Method for the purification of albumin conjugates |
JP2008501714A (ja) | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
WO2006023849A2 (en) | 2004-08-20 | 2006-03-02 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
AU2005277041B2 (en) | 2004-08-23 | 2012-03-22 | Mannkind Corporation | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
WO2007115131A2 (en) * | 2006-03-29 | 2007-10-11 | Guilford F Timothy | Liposomal reduced glutathione and 1-arginine, including other ingredient(s) |
KR20120060245A (ko) | 2005-09-14 | 2012-06-11 | 맨카인드 코포레이션 | 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법 |
WO2007053946A1 (en) | 2005-11-09 | 2007-05-18 | Conjuchem Biotechnologies Inc. | Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin |
FR2896157B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
CN104383546B (zh) | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
ES2354397T3 (es) * | 2007-02-01 | 2011-03-14 | Takeda Pharmaceutical Company Limited | Preparación sólida que comprende alogliptina y pioglitazona. |
US8785396B2 (en) | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
JP5813323B2 (ja) * | 2007-10-24 | 2015-11-17 | マンカインド コーポレイション | 活性薬剤の送達方法 |
HUE025485T2 (en) * | 2007-10-24 | 2016-02-29 | Mannkind Corp | Respiratory dry powder formulation containing GLP-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration |
JP2011506442A (ja) * | 2007-12-11 | 2011-03-03 | コンジュケム バイオテクノロジーズ インコーポレイテッド | インスリン分泌性ペプチド結合体の製剤 |
CN101969934B (zh) * | 2007-12-13 | 2012-11-21 | 国立大学法人九州大学 | 包含药物的纳米颗粒 |
CN103252007B (zh) | 2008-06-13 | 2016-06-22 | 曼金德公司 | 干粉吸入器和用于药物输送的系统 |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
TWI494123B (zh) | 2008-08-11 | 2015-08-01 | Mannkind Corp | 超快起作用胰島素之用途 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US8538707B2 (en) | 2009-03-11 | 2013-09-17 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
BRPI1009619B8 (pt) * | 2009-06-05 | 2021-05-25 | Veroscience Llc | forma de dosagem farmacêutica |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
BRPI1013154B1 (pt) | 2009-06-12 | 2020-04-07 | Mannkind Corp | Micropartículas de dicetopiperazina com áreas de superfície específicas definidas, pó seco compreendendo as referidas micropartículas, método para formação das referidasmicropartículas e formação de micropartículas de fumaril diacetopiperazina, uso das referidas micropartículas e sistema de inalação |
WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
SG10201606220QA (en) | 2011-04-01 | 2016-09-29 | Mannkind Corp | Blister package for pharmaceutical cartridges |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
CA2852536A1 (en) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Methods and compositions for treating pain |
ES2878001T3 (es) | 2012-05-17 | 2021-11-18 | Vtv Therapeutics Llc | Composiciones del activador de la glucocinasa para el tratamiento de la diabetes |
EP2873422A4 (en) | 2012-07-10 | 2015-12-30 | Takeda Pharmaceutical | PHARMACEUTICAL PREPARATION FOR INJECTION |
BR112015000529B1 (pt) | 2012-07-12 | 2022-01-11 | Mannkind Corporation | Inalador de pó seco |
US20140178456A1 (en) * | 2012-08-30 | 2014-06-26 | Udaya Sankar Devanaboyina | Methods and compositions for treating type 2 diabetes and related conditions |
EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
KR102246914B1 (ko) | 2013-03-15 | 2021-04-30 | 맨카인드 코포레이션 | 미세결정성 디케토피페라진 조성물 및 방법 |
CN114848614A (zh) | 2013-07-18 | 2022-08-05 | 曼金德公司 | 热稳定性干粉药物组合物和方法 |
EP3030294B1 (en) | 2013-08-05 | 2020-10-07 | MannKind Corporation | Insufflation apparatus |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
AU2018321157B2 (en) | 2017-08-24 | 2024-03-28 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
JP2021526130A (ja) | 2018-06-12 | 2021-09-30 | ブイティーブイ・セラピューティクス・エルエルシー | インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用 |
MX2022009844A (es) | 2020-02-18 | 2022-09-05 | Novo Nordisk As | Composiciones y usos del peptido similar al glucagon-1 (glp-1). |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4349352A (en) * | 1980-08-14 | 1982-09-14 | Rockefeller University | Test for glucosylated hemoglobin and other glucosylated proteins |
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
GB9409496D0 (en) | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
ATE234625T1 (de) * | 1994-12-23 | 2003-04-15 | Novo Nordisk As | Glp-1 zusammensetzungen mit verlängerter wirkdauer |
TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
GB9712866D0 (en) | 1997-06-18 | 1997-08-20 | Smithkline Beecham Plc | Novel method of treatment |
GB9715298D0 (en) | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
AU3247799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
ID27415A (id) * | 1998-06-30 | 2001-04-05 | Takeda Chemical Industries Ltd | Komposisi farmaseutik |
-
2000
- 2000-06-06 SI SI200030975T patent/SI1133312T1/sl unknown
- 2000-06-06 WO PCT/US2000/015548 patent/WO2000078333A2/en active IP Right Grant
- 2000-06-06 EP EP07111988A patent/EP1849475A1/en not_active Withdrawn
- 2000-06-06 CA CA2349865A patent/CA2349865C/en not_active Expired - Lifetime
- 2000-06-06 PT PT00938173T patent/PT1133312E/pt unknown
- 2000-06-06 US US11/650,410 patent/USRE40876E1/en not_active Expired - Lifetime
- 2000-06-06 EP EP00938173A patent/EP1133312B8/en not_active Expired - Lifetime
- 2000-06-06 DE DE60036367T patent/DE60036367T2/de not_active Expired - Lifetime
- 2000-06-06 AU AU53252/00A patent/AU5325200A/en not_active Abandoned
- 2000-06-06 ES ES00938173T patent/ES2291210T3/es not_active Expired - Lifetime
- 2000-06-06 DK DK00938173T patent/DK1133312T3/da active
- 2000-06-06 AT AT00938173T patent/ATE372782T1/de active
- 2000-06-06 US US09/830,323 patent/US6660716B1/en not_active Ceased
-
2003
- 2003-10-06 US US10/679,746 patent/US7223728B2/en not_active Expired - Lifetime
-
2007
- 2007-11-01 CY CY20071101406T patent/CY1106971T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1106971T1 (el) | 2012-09-26 |
AU5325200A (en) | 2001-01-09 |
DE60036367D1 (de) | 2007-10-25 |
CA2349865C (en) | 2014-08-19 |
EP1133312B8 (en) | 2007-10-17 |
US6660716B1 (en) | 2003-12-09 |
PT1133312E (pt) | 2007-11-30 |
ATE372782T1 (de) | 2007-09-15 |
US20040127414A1 (en) | 2004-07-01 |
ES2291210T3 (es) | 2008-03-01 |
EP1133312B1 (en) | 2007-09-12 |
CA2349865A1 (en) | 2000-12-28 |
DK1133312T3 (da) | 2008-01-02 |
EP1133312A2 (en) | 2001-09-19 |
US7223728B2 (en) | 2007-05-29 |
WO2000078333A2 (en) | 2000-12-28 |
WO2000078333A3 (en) | 2001-07-12 |
DE60036367T2 (de) | 2008-05-29 |
EP1849475A1 (en) | 2007-10-31 |
USRE40876E1 (en) | 2009-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1133312B8 (en) | Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes | |
HK1044280A1 (en) | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus | |
Pederson et al. | Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide | |
Chia et al. | Incretin-based therapies in type 2 diabetes mellitus | |
Idris et al. | Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug | |
Madsbad et al. | Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials | |
MX2008002370A (es) | Exendina para tratar la diabetes y reducir el peso del cuerpo. | |
NZ504258A (en) | Exendin 3 and 4 agonist compounds for the treatment of diabetes | |
EA200870575A1 (ru) | Композиции и способы лечения застойной сердечной недостаточности | |
AU2610899A (en) | N-terminally modified glp-1 derivatives | |
NZ501260A (en) | Treatment of diabetes with thiazolidinedione and metformin | |
MXPA05003346A (es) | Control glicemico mejorado para prediabetes y/o diabetes tipo ii utilizando acido docosahexaenoico. | |
HU9400350D0 (en) | Retard peptides | |
HK1023943A1 (en) | Medicament for the treatment of diabetes mellitus as well as its subsequent disorders | |
UA101166C2 (ru) | Производные пиридин-2-иламино-1,2,4-тиадиазола как активаторы глюкокиназы для лечения сахарного диабета | |
Lingvay et al. | Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS‐1 to‐5 studies | |
MX2022009149A (es) | Compuestos coagonistas de gip/glp1. | |
NO20015932D0 (no) | Fremgangsmåte til å behandle diabetes | |
NZ602583A (en) | Methods of using diacerein as an adjunctive therapy for diabetes | |
Meier et al. | Impact of insulin glargine and lixisenatide on β‐cell function in patients with type 2 diabetes mellitus: A randomized open‐label study | |
WO2020219645A3 (en) | Methods for reducing the weight loss or increasing the weight of a feline in need thereof | |
PE108199A1 (es) | Composicion farmaceutica de tiazolidindiona y sulfonilurea | |
Kitazawa et al. | Combination therapy of glucagon‐like peptide‐1 receptor agonists and insulin for patients who developed diabetes after partial pancreatectomy | |
ES2135353A1 (es) | Utilizacion del 17beta-estradiol, sus analogos y derivados en el tratamiento de la diabetes mellitus y sus manifestaciones. | |
Heise et al. | MANAGEMENT-ORAL HYPOGLYCEMIC AGENTS |